Central and Peripheral Blood Pressure in Treatment of Obstructive Sleep Apnea. (HOSI)

Erling Bjerregaard Pedersen

Status: Unknown

Conditions: Hypertension; Obstructive Sleep Apnea

Treatments: Device: CPAP

Study type: Interventional

Funder types: Other

Identifiers

NCT02078778

BGH-4-2013

M-2013-304-13 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to examine the effect on blood pressure of 3 months of treatment with continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA).

Hypothesis:

1. Central 24-h blood pressure (BP) monitoring hedges day fluctuations in blood pressure more accurately than peripheral 24-h BP monitoring, because the measurement is painless and does not interfere with the patient / subject's activities during the daytime or nighttime sleep.

2. Blood pressure is elevated in patients with OSA and falls during treatment with CPAP.

3. The renal treatment of salt and water is abnormal in OSA, improved during treatment with CPAP.

4. Quality of life improves during treatment with CPAP

Full description

Approximately 20 patients with hypertension and moderate to severe OSA are treated with CPAP 3 months to examine the treatment effect on blood pressure throughout the day, but especially nocturnal, renal treatment of salt and water, and quality of life.

Before and after 3 months of CPAP treatment is made central and peripheral 24-h ambulatory blood pressure monitoring, 24-h urine collection and blood samples.

Enrollment: 20 estimated patients

Sex: All

Ages: 55 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• chronic kidney disease (CKD stage I and II), eGFR 60-90 ml/min/1.73 m2 or eGFR> 90 ml/min/1.73 m2 and proteinuria or other signs of kidney damage.
• Obstructive sleep apnea, apnea hypopnea index (AHI) > 15 (moderate to severe)
• Both men and women
• 55-70 years
• Signed consent form

Exclusion criteria

• Lack of desire to participate
• Malignant disease
• Abuse of drugs or alcohol
• Pregnant and breastfeeding
• Incompensated heart failure
• Atrial fibrillation
• Liver disease (Alanine aminotransferase (ALT) > 200)
• Severe chronic obstructive pulmonary disease (Forced expiratory volume in 1 second <50% predicted)
• Blood pressure difference between the right and left arm> 10/10 mmHg

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Treatment

Experimental group

Description:

Patients with hypertension and moderate to severe OSA is treated with CPAP for 3 months.

Treatment:

Device: CPAP